Explainer
Menopause and hormone therapy explained: the 2025 FDA change
Menopause is reached after 12 months without a period; most women begin the transition between ages 45 and 55, and the average US age of menopause is about 51 to 52.[1][2] Hormone replacement therapy (HRT) relieves most symptoms, and the NHS says its benefits usually outweigh its risks.[3] In November 2025 the FDA began removing most boxed warnings from HRT labels, a move ACOG welcomed while stressing that systemic estrogen still carries risks.[4][5]
Menopause is a normal part of aging, not a disease,[1] but its symptoms vary widely, and US labelling of hormone therapy changed in 2025.[6][4] This page explains the stages, the symptoms, how hormone therapy’s risks and benefits are described, and what the FDA changed.
This page is general information, not medical advice. Whether to use hormone or other treatment depends on your age, symptoms and medical history, so talk to a clinician. Figures here are attributed to the agency or guideline that published them.
The stages
Perimenopause is the transition. The ovaries make less estrogen and progesterone, and periods come less often.[7] WHO says it ends one year after the final period and can last several years.[7]
Menopause is reached after 12 consecutive months without a period that has no other cause. The years after are postmenopause.[1] Most women begin the transition between 45 and 55. NIA gives the average US age of menopause as 52, while NICHD gives 51.[2]
Menopause before 40 is called premature menopause. Surgical or medical menopause is a fall in estrogen after surgery to remove the ovaries or uterus, or treatments such as chemotherapy.[8] Pregnancy is still possible during perimenopause, so WHO recommends contraception until 12 months without a period; see the contraception explainer.[9]
Symptoms and longer-term changes
Symptoms can include hot flashes, night sweats, trouble sleeping, joint and muscle aches, pain during sex, mood changes and difficulty concentrating. Some women have few or none.[6] The NHS says symptoms usually last 7 to 9 years, sometimes longer.[10]
Falling estrogen also has longer-term effects. WHO says bone loss at menopause contributes to higher rates of osteoporosis and fractures, and women’s lower cardiovascular risk compared with men gradually disappears.[11] See the osteoporosis explainer.
Treatment options
NIA says many women do not need treatment. For those who want it, options include lifestyle changes, nonhormonal medicines and hormones.[12]
Non-hormonal medicines. In 2023 the FDA approved Veozah (fezolinetant), the first neurokinin 3 receptor antagonist for moderate to severe hot flashes. It blocks a receptor involved in the brain’s control of body temperature.[13] In November 2025 the FDA announced approval of another non-hormonal treatment for hot flashes.[14]
Hormone replacement therapy (HRT). The NHS describes the balance like this:
- Benefits. HRT relieves most menopause symptoms and helps prevent osteoporosis. For most people the benefits usually outweigh the risks.[3]
- Breast cancer. Combined HRT slightly raises the risk, by around 5 extra cases per 1,000 women taking it for 5 years. Estrogen-only HRT causes little or no increase.[15]
- Clots and stroke. HRT tablets can increase the risk of blood clots and slightly increase the risk of stroke, though both risks are very low. Patches, sprays and gels do not raise clot risk.[16]
- Heart and brain. Research shows little or no effect on coronary heart disease, and it is not known whether HRT reduces dementia risk.[17]
- Vaginal estrogen. Low-dose vaginal estrogen helps with dryness and does not raise the risk of breast cancer or clots.[18]
The 2025 FDA label change
On 10 November 2025 HHS and the FDA announced they were starting to remove the broad boxed (“black box”) warnings from menopause hormone therapy.[4] The FDA said it would work with companies to remove references to cardiovascular disease, breast cancer and probable dementia, but would keep the boxed warning for endometrial cancer on systemic estrogen-alone products.[19] Its labelling will recommend starting systemic HRT within 10 years of menopause onset or before 60.[20] It also announced approval of the first generic version of Premarin in more than 30 years.[14]
The warnings date from the Women’s Health Initiative. The FDA said HRT use fell in the early 2000s after it added boxed warnings following that study. In the FDA’s description, the study found a statistically non-significant increase in the risk of a breast cancer diagnosis. The agency also said participants averaged 63 years old, more than a decade past the average age of menopause, and took a hormone formulation that is no longer commonly used.[21]
The announcement drew mixed reactions:
- The FDA’s case. The agency said women who start HRT within 10 years of menopause may cut cardiovascular disease risk by as much as 50%. NPR reported that the studies the FDA shared to support its decision were published between 1980 and 1996.[22] The NHS says research shows HRT has little or no effect on the risk of coronary heart disease.[17]
- ACOG’s view. The American College of Obstetricians and Gynecologists welcomed the change as removing a barrier to shared decision-making. It said systemic estrogen products are not without risk and should be used after an individual conversation with a clinician. It had also argued that the FDA’s two-hour expert panel was no substitute for a full advisory committee.[5]
Read next
Next in the crash course
Newborn screening explained: the heel prick, the RUSP and 2026 changes
How US newborn screening works, what the heel-prick, hearing and heart tests look for, how the national RUSP list is set and what changed in 2025 and 2026.
Questions readers ask
When does menopause happen?
Most women begin the transition between 45 and 55. NIA gives the average US age of menopause as 52 and NICHD gives 51. Menopause before 40 is called premature menopause.[2][8]
How long do menopause symptoms last?
The NHS says symptoms usually last 7 to 9 years, sometimes longer, and can change over time.[10]
Can you get pregnant during perimenopause?
Yes. WHO says pregnancy is still possible and recommends contraception until 12 consecutive months without a period.[9]
Did the FDA remove the black box warning on HRT?
In November 2025 the FDA began removing the boxed warnings about cardiovascular disease, breast cancer and probable dementia from menopause hormone therapy labels. It kept the boxed warning for endometrial cancer on systemic estrogen-alone products.[4][19]
Does HRT increase breast cancer risk?
The NHS says combined HRT slightly raises it, by around 5 extra cases per 1,000 women taking it for 5 years, and that estrogen-only HRT causes little or no increase.[15]
Sources
· 22 claims from 7 publishers
Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.
- [1]
Menopause, which NIA describes as a normal part of aging rather than a disease, is reached after 12 consecutive months without a period that has no other cause; the time after is called postmenopause. confirmedas of 2026-11-07
- About Menopause · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NIH) · Primary source · About menopause (retrieved 2026-11-07)
- What Is Menopause? · National Institute on Aging (NIH) · Primary source · Overview (retrieved 2026-11-07)
- Menopause - fact sheet · World Health Organization · Primary source · Overview (retrieved 2026-11-07)
- [2]
Most women begin the menopausal transition between 45 and 55; NIA gives the average US age as 52, while NICHD gives 51. confirmedas of 2026-11-07
- What Is Menopause? · National Institute on Aging (NIH) · Primary source · When does menopause happen? (retrieved 2026-11-07)
- About Menopause · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NIH) · Primary source · About menopause (retrieved 2026-11-07)
- [3]
The NHS says the main benefit of HRT is relief of most menopause symptoms, that it helps prevent osteoporosis, and that for most people its benefits usually outweigh its risks. confirmedas of 2026-11-07
- Benefits and risks of hormone replacement therapy (HRT) · NHS · Primary source · Relieving menopause symptoms (retrieved 2026-11-07)
- Benefits and risks of hormone replacement therapy (HRT) · NHS · Primary source · Overview (retrieved 2026-11-07)
- Benefits and risks of hormone replacement therapy (HRT) · NHS · Primary source · Preventing osteoporosis (retrieved 2026-11-07)
- [4]
On 10 November 2025 HHS and the FDA announced they were starting to remove the broad boxed ("black box") warnings from menopause hormone therapy products. confirmedas of 2026-11-07
- HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy · US Food and Drug Administration · Primary source · 2025-11-10 · Press announcement (retrieved 2026-11-07)
- The FDA will lift warnings on hormone therapy for menopause (NPR story by Sydney Lupkin, carried by Wyoming Public Media) · NPR · Secondary source · 2025-11-10 · Opening paragraph (retrieved 2026-11-07)
- HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy · US Food and Drug Administration · Primary source · 2025-11-10 · Dateline (retrieved 2026-11-07)
- [5]
ACOG's president welcomed the label change as improving access, but said systemic estrogen products are not without risk and should be used after an individualised conversation with a clinician, and ACOG had argued that the FDA's two-hour expert panel was no substitute for an advisory committee. confirmedas of 2026-11-07
- ACOG President Says Label Change on Estrogen Will Increase Access to Hormone Therapy · American College of Obstetricians and Gynecologists · Secondary source · 2025-11-10 · Statement (retrieved 2026-11-07)
- ACOG President Says Label Change on Estrogen Will Increase Access to Hormone Therapy · American College of Obstetricians and Gynecologists · Secondary source · 2025-11-10 · Statement (retrieved 2026-11-07)
- The FDA will lift warnings on hormone therapy for menopause (NPR story by Sydney Lupkin, carried by Wyoming Public Media) · NPR · Secondary source · 2025-11-10 · ACOG formal comment, as quoted (retrieved 2026-11-07)
- [6]
Menopause symptoms can include hot flashes, night sweats, trouble sleeping, joint and muscle discomfort, pain during sex, mood changes and difficulty concentrating, though some women have few or none. confirmedas of 2026-11-07
- What Is Menopause? · National Institute on Aging (NIH) · Primary source · Overview (retrieved 2026-11-07)
- Menopause - fact sheet · World Health Organization · Primary source · Changes associated with menopause (retrieved 2026-11-07)
- [7]
During perimenopause, the menopausal transition, the ovaries produce less estrogen and progesterone and periods become less frequent; WHO says it ends one year after the final period and can last several years. confirmedas of 2026-11-07
- About Menopause · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NIH) · Primary source · About menopause (retrieved 2026-11-07)
- About Menopause · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NIH) · Primary source · About menopause (retrieved 2026-11-07)
- Menopause - fact sheet · World Health Organization · Primary source · Key facts (retrieved 2026-11-07)
- [8]
Menopause before 40 is called premature menopause, and surgical or medical menopause refers to a fall in estrogen after surgery to remove the ovaries or uterus, or treatments such as chemotherapy. confirmedas of 2026-11-07
- Menopause - fact sheet · World Health Organization · Primary source · Overview (retrieved 2026-11-07)
- About Menopause · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NIH) · Primary source · About menopause (retrieved 2026-11-07)
- [9]
Pregnancy is still possible during perimenopause, and WHO recommends contraception until 12 consecutive months without a period. confirmedas of 2026-11-07
- Menopause - fact sheet · World Health Organization · Primary source · Changes associated with menopause (retrieved 2026-11-07)
- [10]
The NHS says menopause symptoms usually last 7 to 9 years, sometimes longer, and can change over that time. confirmedas of 2026-11-07
- Symptoms of menopause and perimenopause · NHS · Primary source · How long symptoms last (retrieved 2026-11-07)
- [11]
WHO says bone loss at menopause contributes to higher rates of osteoporosis and fractures, and that women's lower cardiovascular risk compared with men gradually disappears as estrogen falls. confirmedas of 2026-11-07
- Menopause - fact sheet · World Health Organization · Primary source · Changes associated with menopause (retrieved 2026-11-07)
- Menopause - fact sheet · World Health Organization · Primary source · Changes associated with menopause (retrieved 2026-11-07)
- [12]
NIA says many women do not need treatment for menopause symptoms, and options for those who want it include lifestyle changes, nonhormonal medications and hormones. confirmedas of 2026-11-07
- What Is Menopause? · National Institute on Aging (NIH) · Primary source · Treatment (retrieved 2026-11-07)
- [13]
In May 2023 the FDA approved Veozah (fezolinetant), the first neurokinin 3 receptor antagonist for moderate to severe menopausal hot flashes; it blocks a receptor involved in the brain's regulation of body temperature. confirmedas of 2026-11-07
- FDA Approves Novel Drug to Treat Moderate to Severe Hot Flashes Caused by Menopause · US Food and Drug Administration · Primary source · 2023-05-12 · Press announcement (retrieved 2026-11-07)
- FDA Approves Novel Drug to Treat Moderate to Severe Hot Flashes Caused by Menopause · US Food and Drug Administration · Primary source · 2023-05-12 · Press announcement (retrieved 2026-11-07)
- [14]
Alongside the label change the FDA announced approval of a generic version of Premarin (conjugated estrogens), the first in more than 30 years, and of a non-hormonal treatment for moderate to severe hot flashes. confirmedas of 2026-11-07
- HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy · US Food and Drug Administration · Primary source · 2025-11-10 · Press announcement (retrieved 2026-11-07)
- HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy · US Food and Drug Administration · Primary source · 2025-11-10 · Press announcement (retrieved 2026-11-07)
- [15]
The NHS says combined HRT slightly increases breast cancer risk, by around 5 extra cases per 1,000 women taking it for 5 years, while estrogen-only HRT causes little or no increase. confirmedas of 2026-11-07
- Benefits and risks of hormone replacement therapy (HRT) · NHS · Primary source · Breast cancer (retrieved 2026-11-07)
- Benefits and risks of hormone replacement therapy (HRT) · NHS · Primary source · Breast cancer (retrieved 2026-11-07)
- [16]
The NHS says HRT tablets can increase the risk of blood clots and slightly increase the risk of stroke, though both risks are very low, while patches, sprays and gels do not raise clot risk. confirmedas of 2026-11-07
- Benefits and risks of hormone replacement therapy (HRT) · NHS · Primary source · Blood clots (retrieved 2026-11-07)
- Benefits and risks of hormone replacement therapy (HRT) · NHS · Primary source · Stroke (retrieved 2026-11-07)
- [17]
The NHS says research shows HRT has little or no effect on coronary heart disease risk and that it is not known whether HRT reduces dementia risk. confirmedas of 2026-11-07
- Benefits and risks of hormone replacement therapy (HRT) · NHS · Primary source · Other conditions (retrieved 2026-11-07)
- Benefits and risks of hormone replacement therapy (HRT) · NHS · Primary source · Other conditions (retrieved 2026-11-07)
- [18]
The NHS says low-dose vaginal estrogen helps with vaginal dryness and does not increase the risk of breast cancer or blood clots. confirmedas of 2026-11-07
- Benefits and risks of hormone replacement therapy (HRT) · NHS · Primary source · Vaginal oestrogen (retrieved 2026-11-07)
- [19]
The FDA said it would work with companies to remove references to cardiovascular disease, breast cancer and probable dementia from the boxed warnings, but would keep the boxed warning for endometrial cancer on systemic estrogen-alone products. confirmedas of 2026-11-07
- HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy · US Food and Drug Administration · Primary source · 2025-11-10 · Press announcement (retrieved 2026-11-07)
- HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy · US Food and Drug Administration · Primary source · 2025-11-10 · Press announcement (retrieved 2026-11-07)
- [20]
The FDA said its labelling would recommend starting systemic HRT within 10 years of menopause onset or before age 60. confirmedas of 2026-11-07
- HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy · US Food and Drug Administration · Primary source · 2025-11-10 · Press announcement (retrieved 2026-11-07)
- [21]
The FDA said HRT use fell in the early 2000s after it applied boxed warnings following a Women's Health Initiative study, which the agency described as finding a statistically non-significant increase in breast cancer diagnosis risk; it said participants averaged 63 years old, over a decade past the average age of menopause, and took a hormone formulation no longer in common use. confirmedas of 2026-11-14
- HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy · US Food and Drug Administration · Primary source · 2025-11-10 · Press announcement (retrieved 2026-11-07)
- HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy · US Food and Drug Administration · Primary source · 2025-11-10 · Press announcement (retrieved 2026-11-07)
- [22]
The FDA's announcement said women who start HRT within 10 years of menopause may cut cardiovascular disease risk by as much as 50% and Alzheimer's disease by 35%; NPR reported that the studies the agency shared in support were published between 1980 and 1996. disputedas of 2026-11-07
- HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy · US Food and Drug Administration · Primary source · 2025-11-10 · Press announcement (retrieved 2026-11-07)
- The FDA will lift warnings on hormone therapy for menopause (NPR story by Sydney Lupkin, carried by Wyoming Public Media) · NPR · Secondary source · 2025-11-10 · Supporting studies (retrieved 2026-11-07)
Revision history (3)
- Changed the status of the claim carrying NPR's report that the WHI risks were overstated from confirmed to reported, since it rests on one outlet.
- Replaced NPR's single-outlet line that the WHI risks were overstated with the FDA's own attributed description of the study.
- Page created.
Created Nov 7, 2026. Last reviewed by an editor on Nov 8, 2026. Next scheduled review: Feb 7, 2027.
Cite this page
"Menopause and hormone therapy explained: the 2025 FDA change." ContentLora, updated Nov 14, 2026. https://contentlora.com/explain/menopause-explained
Spotted an error? Suggest a correction or emailcorrections@contentlora.com.